PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|April 25, 2014
Exhibits Drive Attendee Action at Interphex 2014
Author(s)Pharmaceutical Technology Editors
INTERPEHX 2014 attendees tested their driving skills in a racecar simulator at the Federal Equipment booth.
Advertisement
Visitors to INTERPEHX 2014 tested their driving skills in a racecar simulator at the Federal Equipment booth. Pharmaceutical Technology’s publisher, Mike Tracey (pictured) was a participant.
INTERPHEX 2014 attracted 12,000 attendees to more that 650 exhibitors at the Javits Center in New York City on March 18-20. INTERPHEX 2015 will be held April 21-23 in New York.
Federal Equipment has more than 50 years of experience in the processing equipment industry, providing used equipment for solid dose, sterile, API and related pharmaceutical process industries.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement